We are live on ! Find out more
AGN

Allergan plc
AGN

Delisted

AGN was delisted on the 8th of May, 2020.

1,107 hedge funds and large institutions have $79B invested in Allergan plc in 2016 Q2 according to their latest regulatory filings, with 169 funds opening new positions, 500 increasing their positions, 363 reducing their positions, and 172 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 500 | Existing positions reduced: 363

5% more call options, than puts

Call options by funds: $4.83B | Put options by funds: $4.61B

2% less first-time investments, than exits

New positions opened: 169 | Existing positions closed: 172

1% less funds holding

Funds holding: 1,1191,107 (-12)

15% less capital invested

Capital invested by funds: $92.6B → $79B (-$13.6B)

26% less funds holding in top 10

Funds holding in top 10: 155115 (-40)

Holders
1,107
Holders Change
-12
Holders Change %
-1.07%
% of All Funds
29.54%
Holding in Top 10
115
Holding in Top 10 Change
-40
Holding in Top 10 Change %
-25.81%
% of All Funds
3.07%
New
169
Increased
500
Reduced
363
Closed
172
Calls
$4.83B
Puts
$4.61B
Net Calls
+$225M
Net Calls Change
+$2.19B
Name Holding Trade Value Shares
Change
Change in
Stake
UBS AM
26
UBS AM
Illinois
$661M -$85.6M -371,331 -11%
Goldman Sachs
27
Goldman Sachs
New York
$642M -$199M -863,746 -24%
EM
28
Elliott Management
New York
$632M +$54.9M +237,949 +10%
Macquarie Group
29
Macquarie Group
Australia
$632M +$310M +1,345,095 +97%
GE
30
General Electric
Ohio
$619M +$74.3M +322,108 +14%
Invesco
31
Invesco
Georgia
$496M +$78.6M +340,998 +19%
Deutsche Bank
32
Deutsche Bank
Germany
$496M +$69.7M +302,146 +16%
Lazard Asset Management
33
Lazard Asset Management
New York
$495M +$485M +2,101,665 +5,272%
VAM
34
Veritas Asset Management
United Kingdom
$492M +$491M +2,129,805 New
EIP
35
Epoch Investment Partners
New York
$478M +$168M +728,022 +54%
Neuberger Berman Group
36
Neuberger Berman Group
New York
$467M +$187M +810,232 +67%
FAM
37
Fred Alger Management
New York
$466M +$142M +615,855 +44%
BG
38
Baupost Group
Massachusetts
$463M +$64.6M +280,391 +16%
Viking Global Investors
39
Viking Global Investors
Connecticut
$448M -$678M -2,942,254 -60%
Parnassus Investments
40
Parnassus Investments
California
$444M +$186M +805,787 +72%
Wells Fargo
41
Wells Fargo
California
$415M +$3.57M +15,479 +0.9%
PCM
42
Pentwater Capital Management
Florida
$407M -$703M -3,050,500 -63%
TIM
43
Thornburg Investment Management
New Mexico
$397M +$226M +981,355 +133%
EVM
44
Eaton Vance Management
Massachusetts
$396M +$209M +908,569 +113%
DCP
45
DSM Capital Partners
Florida
$390M +$34.4M +149,316 +10%
Massachusetts Financial Services
46
Massachusetts Financial Services
Massachusetts
$368M -$187M -809,264 -34%
PI
47
Putnam Investments
Massachusetts
$359M +$44.3M +192,186 +14%
Dimensional Fund Advisors
48
Dimensional Fund Advisors
Texas
$359M -$49.3K -214 -0%
O
49
OppenheimerFunds
New York
$355M -$55.3M -240,055 -14%
IC
50
Institutional Capital
Illinois
$355M +$10.3M +44,876 +3%

AGN Hedge Fund Activity: Q2 2016 in Review

1,107 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Allergan plc (AGN) for Q2 2016, worth a combined $79B — down 15% from $92.6B a quarter earlier.

Sellers outnumbered buyers: 172 funds closed out of AGN and 169 opened new positions — a net loss of 3 holders — while 363 trimmed existing stakes and 500 added.

The largest buyer was Icahn Carl, opening a new position worth an estimated $784M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.03B.

  • 1,107 institutional investors held Allergan plc (AGN) as of Q2 2016, down from 1,119 in Q1 2016.
  • Funds reported $79B of Allergan plc stock for Q2 2016, down 15% quarter-over-quarter.
  • 169 funds opened new Allergan plc positions in Q2 2016 and 172 closed out, a net change of -3 holders.
  • The largest Allergan plc buyer in Q2 2016 was Icahn Carl, an estimated $784M added.
  • The largest Allergan plc seller in Q2 2016 was T. Rowe Price Associates, an estimated $1.03B sold.

Based on aggregated 13F filings for Q2 2016.